Home・Elenco Azioni・Genmab A-S
Search

Genmab A-S

Aperta

1,989.5 0.18

Neutrale

Aggiornamento del prezzo 11 ago 2026, 14:54 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1960.5

Massimo

2006

Metriche Chiave

By Trading Economics

Entrata

21M

52M

Vendite

-169M

896M

P/E

Media del settore

21.639

68.51

EPS

8.48

Margine di Profitto

5.818

Dipendenti

3,088

EBITDA

-30M

215M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-1.49% downside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

8.5B

113B

Apertura precedente

1989.32

Chiusura precedente

1989.5

Genmab A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 ago 2026, 23:56 UTC

RingCentral Inc. shares advanced in after-market trading, continuing a month-long upward trend and remaining significantly above the 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Aramark shares are higher in after-market trading, recovering from an early decline. The stock remains below its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

CF Industries Holdings Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock is below its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Yelp Inc. shares rose slightly in after-market trading, despite being below the 20-day moving average and near the lower end of their one-month range.

LeggI

10 ago 2026, 23:56 UTC

NN Inc shares are higher in after-market trading, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

LeggI

10 ago 2026, 23:56 UTC

Johnson Controls International PLC shares are higher in after-market trading, reflecting a modest uptick following Monday's close. The stock remains above its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

B&G Foods Inc. shares are lower in after-market trading, reflecting broader market declines and cautious sentiment following recent labor market data.

LeggI

10 ago 2026, 23:56 UTC

Dynatrace Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment is influenced by recent economic data.

LeggI

10 ago 2026, 23:56 UTC

New Fortress Energy shares are higher in after-market trading, reaching 2.94% above Monday's close, significantly above the 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Social Media

NetApp Inc shares are trading higher in after-market hours following an upgrade from Morgan Stanley, driven by increased demand for storage solutions.

LeggI

10 ago 2026, 23:56 UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

LeggI

10 ago 2026, 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

LeggI

10 ago 2026, 23:56 UTC

Target Corp shares declined in after-market trading, reflecting a directional move since Monday's close. The stock remains above its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Correlated Moves

Host Hotels & Resorts Inc. is trading lower in after-market hours, reflecting broader declines in small-cap stocks and cautious market sentiment following a recent jobs report.

LeggI

10 ago 2026, 23:56 UTC

Correlated Moves
ETF Constituents

Financial Select Sector SPDR Fund declines in after-market trading as top holdings Visa, FIS, and PayPal post losses amid flat U.S. markets.

LeggI

10 ago 2026, 23:56 UTC

Enovix Corp shares are higher in after-market trading, showing strength above their 20-day moving average amid cautious market optimism following recent labor data.

LeggI

10 ago 2026, 23:56 UTC

Correlated Moves

indie Semiconductor Inc's shares are lower in after-market hours, influenced by broader market caution and a decline in the Russell 2000 Index.

LeggI

10 ago 2026, 23:56 UTC

Hawaiian Electric Industries shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Quantumscape Corp shares traded lower in after-market hours, with no specific news identified. The stock remains above its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Tower Semiconductor shares are higher in after-market hours, with no specific news identified. The stock remains well above its 20-day moving average.

LeggI

10 ago 2026, 23:56 UTC

Correlated Moves

US 5Y Treasury Bond Index trades roughly flat as traders reassess September rate hike odds after a jobs report showed a decline of 23,000 jobs.

LeggI

10 ago 2026, 23:56 UTC

Correlated Moves

US 10Y Treasury Bond Index trades near unchanged as traders reassess September rate hike odds following a jobs report indicating a decline of 23,000 jobs.

LeggI

10 ago 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

LeggI

10 ago 2026, 23:52 UTC

Correlated Moves
ETF Constituents
Macro News
Social Media

Energy Select Sector SPDR Fund lower in after-market hours despite crude oil prices rising to $82.25 amid concerns over the Strait of Hormuz reopening.

LeggI

10 ago 2026, 23:52 UTC

Event
News
Social Media

Plug Power shares are higher in after-market trading following strong second-quarter results that exceeded analyst expectations and an improved revenue growth outlook.

LeggI

10 ago 2026, 23:51 UTC

Modine Manufacturing Co shares are higher in after-market trading, buoyed by last Friday's labor report that reduced expectations for Federal Reserve rate hikes.

LeggI

10 ago 2026, 23:51 UTC

Correlated Moves

Stanley Black & Decker Inc shares declined in after-market trading amid weak market performance and downward pressure from recent labor market data.

LeggI

10 ago 2026, 23:51 UTC

Shoals Technologies Group Inc shares are lower in after-market trading. Broader market sentiment is affected by a recent labor report and Fed rate hike expectations.

LeggI

10 ago 2026, 23:51 UTC

Hilltop Holdings Inc is trading lower in after-market hours, continuing a decline since Monday's close amid broader market sentiment influenced by a weak labor report.

LeggI

Genmab A-S Previsione

Obiettivo di Prezzo

By TipRanks

-1.49% in calo

Previsioni per 12 mesi

Media 2,493.35 DKK  -1.49%

Alto 3,320 DKK

Basso 308.417 DKK

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Genmab A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

7 ratings

3

Acquista

2

Mantieni

2

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Genmab A-S - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat